GlassScriptPhysician profile
Donna Murtaugh
NPI 1225335920
$1,736.89
in general payments reported to CMS, 2019-2025
22 companies · $601 in 2025
The $601 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $214 · 2023: $303 · 2024: $354 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.51 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $205.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $175.00 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $141.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.40 | 2021-2025 | Jardiance |
| Abbott Laboratories | $116.99 | 2025 | Diamondback Peripheral |
| Neurocrine Biosciences, INC. | $105.67 | 2022-2024 | Ingrezza |
| Pfizer INC. | $84.96 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $68.52 | 2021-2025 | Breztri, Airsupra |
| Abbvie INC. | $64.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $41.00 | 2025 | |
| Abiomed | $38.06 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.14 | 2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $28.38 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.61 | 2024 | Dificid |
| Sun Pharmaceutical Industries INC. | $23.44 | 2021 | |
| Hologic Sales and Service, LLC | $23.04 | 2025 | Aptima |
| Ultragenyx Pharmaceutical INC. | $21.09 | 2021 | |
| Amgen INC. | $20.42 | 2023 | Prolia, Evenity |
| Idorsia Pharmaceuticals US INC | $16.94 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $16.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Murtaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.